Abstract
The marked progress in controlling emesis caused by cisplatin characterizes the current status of antiemetic treatment for all chemotherapy. Cisplatin has provided a model for antiemetic studies. Strategies for controlling cisplatin-induced emesis are at least as successful when applied to other chemotherapy, and persistent problems such as delayed emesis and the emesis associated with consecutive-day chemotherapy are also similar to or less severe than those observed with cisplatin. The purpose of this report is twofold: first to outline briefly therapy for cisplatin-induced emesis as illustrated by several new studies, and, second, to report on a new trial that incorporates some different strategies in the control of delayed emesis after cisplatin.
Original language | English (US) |
---|---|
Pages (from-to) | 86-91 |
Number of pages | 6 |
Journal | Oncology (Switzerland) |
Volume | 53 |
Issue number | 1 |
DOIs | |
State | Published - Jan 1 1996 |
Keywords
- Cisplatin
- Delayed emesis
- Dexamethasone
- Ondansetron
ASJC Scopus subject areas
- Oncology
- Cancer Research